| First Author | Wu KC | Year | 2021 |
| Journal | Toxicol Appl Pharmacol | Volume | 418 |
| Pages | 115494 | PubMed ID | 33722668 |
| Mgi Jnum | J:306847 | Mgi Id | MGI:6718217 |
| Doi | 10.1016/j.taap.2021.115494 | Citation | Wu KC, et al. (2021) Tpl2 kinase regulates inflammation but not tumorigenesis in mice. Toxicol Appl Pharmacol 418:115494 |
| abstractText | Tumor progression locus 2 (Tpl2, gene name MAP3K8), a mitogen-activated protein kinase, is widely expressed in immune and non-immune cells to integrate tumor necrosis factor (TNF), toll-like receptors (TLRs), and interleukin-1 (IL1) receptor signaling to regulate inflammatory response. Given its central role in inflammatory response, Tpl2 is an attractive small molecule drug target. However, the role of Tpl2 as an oncogene or tumor suppressor gene remains controversial, and its function outside immune cells is not understood. We therefore utilized a Tpl2 kinase dead (Tpl2-KD) mouse model in an 18-month aging study to further elucidate Tpl2 effects on lifespan and chronic disease. Histopathological studies revealed the incidence and severity of spontaneous tumors and non-neoplastic lesions were comparable between wild type and Tpl2-KD mice. The only finding was that male Tpl2-KD mice had higher bodyweight and an increased incidence of liver steatosis, suggesting a sex-specific role for Tpl2 in hepatic lipid metabolism. In conclusion, loss of Tpl2 kinase activity did not lead to increased tumorigenesis over aging in mice but affected likely alterations in lipid metabolism in male animals. |
